Evidence quality assessment of sodium tanshinone IIA sulfonate injection intervention coronary heart disease angina pectoris: An overview of systematic reviews and meta-analyses

Author:

Peng Lufeng1ORCID,Fan Maoxia2,Li Junhai2,Chen Wenqiang2

Affiliation:

1. Qilu Hospital of Shandong University, Jinan, Shandong Province, China

2. Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.

Abstract

Background: Sodium tanshinone IIA sulfonate injection (STS) is widely used in the clinical treatment of coronary heart disease angina pectoris (CHDAP). This article systematically summarizes and evaluates the available evidence for STS in the treatment of AP, and assess its quality. Methods: Two researchers searched and extracted 8 databases for systematic reviews (SRs)/meta-analyses (MAs), and independently assessed the methodological quality, risk of bias, reporting quality, and quality of evidence of SRs/MAs included in randomized controlled trials (RCTs). Tools used included the Assessment of Multiple Systematic Reviews 2 (AMSTAR-2), the risk of bias in systematic (ROBIS) scale, the list of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Results: This overview includes 11 SRs/MAs that use quantitative calculations to comprehensively evaluate various efficacies of STS in AP intervention. The methodological quality, reporting quality, risk of bias, and quality of evidence for outcome measures of SRs/MAs were all unsatisfactory. All SRs/MAs are of low quality according to the results of the AMSTAR-2 assessment, and only a small number of SRs/MAs were assessed as low risk of bias based on the results of the ROBIS assessment, and none of the SRs/MAs has been fully reported on the checklist. According to GRADE system, 33 outcomes were extracted from the included SRs/MAs for evaluation, of which 12 were rated as moderate-quality evidence, 7 as low-quality evidence, and 14 as very low-quality evidence. Limitations included the lack of essential items such as protocol registration, screening of duplicate studies, provision of a list of excluded studies and assessment of publication bias. Conclusion: Tanshinone IIA Sulfonate Sodium Injection may be an effective and safe treatment method. However, further standardized, comprehensive SRs/MAs and RCTs are needed to provide evidence-based medical support.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference35 articles.

1. Clinical research and practice of the combination of coronary heart disease and syndrome.;Wang;J Tradit Chin Med,2015

2. Guidelines for the diagnosis and treatment of common diseases in traditional Chinese medicine (Western medicine disease part) coronary heart disease angina pectoris.;Zhong;Mod Distance Educ Trad Chin Med China,2011

3. 2014 AHA/ACC Guideline for the management of patients with nonst-elevation acute coronary syndromes: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines.;Amsterdam;Circulation,2014

4. Treatment strategies for peripheral artery disease.;McCann;Expert Opin Pharmacother,2009

5. The clinical advantages of traditional Chinese medicine in the prevention and treatment of coronary heart disease and reflections on the evaluation of the efficacy.;Bi;J Tradit Chin Med,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3